Prevention of atherosclerosis by SGLT2 inhibitor; multicenter, randomized controlled study
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000018440
- Lead Sponsor
- Department of Cardiovascular Medicine, Saga University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 479
Not provided
1) Type 1 diabetes 2) Has history of severe ketosis, diabetic coma, or precoma within 6 months 3) Has severe infection, serious trauma, or pre or post surgery (including carotid endarterectomy and stent implantation) 4) With severe renal dysfunction (eGRF <45 mL/min/1.73m2 or patient undergoing artificial dialysis) 5) Has history of myocardial infarction, angina, percutaneous transluminal coronary angioplasty, coronary artery bypass graft, cerebral infarction, intracranial hemorrhage, subarachnoid hemorrhage, transient ischemic attacks within 3 months before initiation of the study 6) Heart failure patient whose NYHA functional classification is III or IV 7) Has history of administration of SGLT-2 within 1 month before initiation of the study 8) Pregnant, possibly pregnant, planned to become pregnant or nursing women 9) Has history of hypersensitivity to ipragliflozin or any other excipient of ipragliflozin 10) Are considered not eligible for the study by the attending doctor due to other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method